(Q37774238)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20644567%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

review article

1 reference

title

Pegylated interferons alpha2a and alpha2b in the treatment of chronic hepatitis C (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20644567%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20644567%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Mariagrazia Rumi

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20644567%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

author name string

Massimo Colombo

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20644567%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

language of work or name

English

0 references

publication date

20 July 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20644567%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Gastroenterology & Hepatology

8 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20644567%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

volume

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20644567%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20644567%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

page(s)

485-494

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20644567%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nrgastro.2010.101

8 February 2020

exact match

0 references

cites work

The prevalence of hepatitis C virus infection in the United States, 1999 through 2002

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.101

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.101

Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.101

Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.101

The changing epidemiology of hepatitis C virus infection in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.101

Worldwide mortality from cirrhosis: an update to 2002.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.101

Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.101

Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.101

Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.101

The long and winding road leading to the identification of the hepatitis C virus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.101

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.101

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.101

Pegylation: a novel process for modifying pharmacokinetics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.101

Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.101

Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.101

Pharmacokinetics of pegylated interferons: what is misleading?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.101

Review article: pegylated interferons: chemical and clinical differences

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.101

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.101

Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.101

Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.101

Antiviral actions of interferons

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.101

IL-28, IL-29 and their class II cytokine receptor IL-28R

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.101

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.101

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.101

Viruses and interferon: a fight for supremacy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.101

Current and future concepts in hepatitis C therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.101

Therapy of hepatitis C: from empiricism to eradication

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.101

Actions of cytokines on the immune response and viral interactions: an overview

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.101

The interferons. Mechanisms of action and clinical applications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.101

A prospective, randomized trial comparing lymphoblastoid to recombinant interferon alfa 2a as therapy for chronic hepatitis C.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.101

Pegylated IFN-alpha2a and ribavirin in the treatment of hepatitis C.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.101

A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.101

Structural and biologic characterization of pegylated recombinant IFN-alpha2b

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.101

Twice-weekly administration of peginterferon-alpha-2b improves viral kinetics in patients with chronic hepatitis C genotype 1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.101

Optimal dosing frequency of pegylated interferon alfa-2b monotherapy for chronic hepatitis C virus infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.101

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.101

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.101

Ethics in clinical research

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.101

Predictors of response of US veterans to treatment for the hepatitis C virus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.101

Pegylated interferon alpha2b versus pegylated interferon alpha2a for chronic hepatitis C: the unreached goal of superiority

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.101

PEG IFN alfa-2a vs. alfa-2b: And the winner is …?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.101

Results of the IDEAL trial: "Mirror, mirror on the wall ... which's the fairest peg-interferon of them all?"

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.101

Peginterferon Alfa-2B versus peginterferon Alfa-2A with ribavirin for the treatment of chronic hepatitis C: the pursuit of an ideal

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.101

International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.101

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.101

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.101

Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.101

Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.101

Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.101

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.101

Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.101

Clinical trial design and evidence-based outcomes in the study of liver diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.101

Treatment predictors of a sustained virologic response in hepatitis B and C.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.101

Do differences in pegylation of interferon alfa matter?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.101

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.101

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.101

Resistance to direct antiviral agents in patients with hepatitis C virus infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.101

Interferon-induced antiviral actions and their regulation.

31 March 2020

1 reference

12 December 2020

Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C.

1 reference

12 December 2020

Pegylation of interferon alfa: structural and pharmacokinetic properties

1 reference

12 December 2020

The pattern of pegylated interferon-alpha2b and ribavirin treatment failure in cirrhotic patients depends on hepatitis C virus genotype

1 reference

12 December 2020

10.1038/NRGASTRO.2010.101

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20644567%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

1 reference